New York, June 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Immuno-Oncology (IO) - Thematic Intelligence" - https://www.reportlinker.com/p06465094/?utm_source=GNW
The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation to remain the most valuable IO sector. 2022–23 has seen some IO success, but no major IO breakthrough has happened. Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.
Key Highlights
Forecast includes 8 countries
Forecast covers 2022-2028
Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics
Scope
- This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.
Reasons to Buy
OBTAIN IMMUNO-ONCOLOGY MARKET ASSESSMENT AND FORECAST ACROSS MULTIPLE REGIONS
GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES
Our indication specific forecast models answer questions such as -
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Read the full report: https://www.reportlinker.com/p06465094/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
